Portfolio interview Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

What are the good scientific practice domains?

A
  1. Professional practice
  2. Scientific practice
  3. Clinical practice
  4. Research, development and innovation
  5. Clinical leadership
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Describe the NHS constitution

A
  1. The NHS provides a comprehensive service, available to all
  2. Access is based on clinical need, not ability to pay
  3. Aspires to the highest standards of excellence and professionalism
  4. The patient is at the heart of everything we do
  5. Work across organisational boundaries eg local authority, public, private and voluntary organisations
  6. Best value for money
  7. Accountable to the public, communities and patients it serves
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the NHS values?

A
  1. Working together for patients
  2. Respect and dignity
  3. Commitment to quality care
  4. Compassion
  5. Improving lives
  6. Everyone counts
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe CML and its clinical presentation.

A

CML, chronic myeloid leukaemia:
Myeloproliferative neoplasm originating from pluripotent stem cells - granulocytes are the main component

Usually developes slowly, presents with mild symptoms such as fatigue, night sweats, weight loss, anaemia and bone pain. ~50% are asymptomatic and are discovered by high wbc count observed on a routine blood test.

Commonly occurs around 60y/o but can occur in any age. 15% of leukaemiaswith slight male predisposition.

Characterised by a reciprocal translocation between chromosomes 9 and 22.
t(9;22)(q34.1;q11.2) - Philadelphia chromosome in 95% BCR-ABL1. 5% may have variant or cryptic translocation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe ALL

A

ALL, acute lymphoblastic leukaemia.
Second most common leukaemia in adults. Malignant transformation of lymphoid progenitor cells in bone marrow. >20% blasts in BM or blood.
80% occur in children. 75% of adult all is B-ALL, 25% T-ALL

Etv6-runx1 - common in children

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe QF-PCR and its use in prenatal testing

A

Screening of aneuploidy for T13/18/21 and XY sex abnormalities
Preformed on CVS/Amnio
Uses highly polymorphic STRs that are identifiable using fluorescent labelled primers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is CPM ( confined placental mosaicism)

A

The presence of chromosomal abnormalities in the extra-embryonic tissue, which are absent from the fetal tissue.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How does CPM arise

A

Mitotic CPM - trisomic cell line arises from postzygotic mitotic duplucation of one chromosome in the progenitors of a placental cell lineage eg trophoblast.

Meiotic CPM - trisomic zygote is rescued at the blastocyst developmental stage by loss of the extra chromosome during mitotic cell division in the embryonic progenitor cells (while progenitors in the placenta remain trisomic). May be associated with UPD - thoerically 1/3 should show UPD. May affect in uterine growth.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What would you do to rule out cpm or mosaicism suspected on QF-PCR

A

FISH on short term and long term cultures - according to European guidelines ‘where cpm is likely cause of discrepant result, ultrasound monitoring should be recommended on the report’

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is MS-MLPA and what are its uses

A

Methylation specific ligation dependant probe amplification;
Variant of standard MLPA which combines copy number repeat with methylation sensitive restriction enzyme (HhaI) to produce a semi-quantitative interpretation.

Enables the detection of imprinting pattern in PWS or Angelman, beckwith-Wiedemann/Russel silver syndrome.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Clinical features of Prader-Willi

A
Hearing loss
Developmental delay - particularly language
Excessive eating, raised bmi
Hypotonia (floppy)
Shorter stature
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe sensitivity and specificity

A

Sensitivity; the ability of a test to correctly identify patients with a disease.

Sensitivity = true positives ÷ (true positives + false negatives)

Specificity; the ability of a test to correctly identify patients without a disease

Specificity = true negatives ÷ ( the negatives + false positives)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe an Autosomal Dominant disorder ( Huntington Disease)

A

Progressive degeneration of nerve cells in brain = tremors, seizures and contraction of muscles. Progressive disease.
CAG trinucleotide repeat in the HTT gene. 10-35x = normal. 36-120+ = production of abnormally long Huntingtin protein which is cut up by the cell to produce smaller fragments which aberrantly bind to neurons impairing function.
CAG repeat displays anticipation through generations.
Presents in 30-40 y/o

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Define validation and verification

A

Validation = are we doing the correct test

Verification = are we doing the test correctly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe an autosomal recessive disease (Cystic fibrosis)

A

Carrier frequency 1/22 in mid Trent region.
Usually characterised by airflow limitations with recurrent infections and nutritional deficiency due to exocrine pancreatic impairment. Male infertility due to congenital absence of vans deferens or bilateral ejaculatory duct obstruction.
CFTR chromosome 7. Mutations effect the transport of chloride across membrane. Delta F508 80% in Trent region.
Newborns = failure to produce first bowl movement (meconium ileus). Failure to thrive, infections.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the different types of CF mutation?

A

Class 1: no functional CFTR created (22% of CF with at least one mut)
Class 2: CFTR protein is created but misfolds, keeping it from moving to cell surface. (eg DeltaF508) (88% of CF with at least one mut)
Class 3: CFTR protein is created And moves to cell surface but channel gate doesn’t open (6%)
Class 4: CFTR protein is created and moves to cell surface but channel is faulty.
Class 5: normal CFTR protein is created and moves to the cell surface but in insufficient quantities.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the purpose of Poly T analysis for CF and in which cases would you test

A

Can function as a CFTR mutation in some CF related cases and can effect the severity of other mutations (R117H). Should not be performed routinely in the context of carrier testing relatives, partners of carriers/patients, or echogenic bowel referrals.
Performed on:
1. Obstructive azoospermia cases
2. Diagnostic CF referrals with R117H
3. Bronchiectasis or pancreatitis cases with one mutation detected
4. Testing clinically requested, such as general male infertility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What might cause a false negative result on CF kit testing

A

Mutation not covered by kit

Variant within the primer binding site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Describe an X-linked disorder (Fragile X)

A

Moderate-severe intellectual disability, long face, large ears and macroorchidism.
Expansion of CGG repeat un 5’UTR of FMR1
<45= normal
46-58= intermediate
59-200= premutation ( may cause FXTAS in males/females, or POI in females)
200+ (methylated) = fragile X

20
Q

What are the Cauldicot principles?

A
  1. Justify the purpose for use of confidential info
  2. Use only when absolutely necessary
  3. Use minimum info required
  4. Access on strict need-to-know basis
  5. Everyone must understand responsibilities
  6. Understand and comply with the law
  7. Duty to share can be just as important as duty to patient confidentiality
21
Q

Describe your research project and why it is important?

A

PRT testing on cfDNA (paralogue ratio testing) - identifies copy number change at a specific locus by comparing the quantitative difference with a control target locus - ratio impalance. Eg. Circulating Tumour DNA.
Only a single set of primers that amplifies both the target and ref sequence.
Multiple PRT assays can be run simultaneously using different dyes, so long as the products are distinct sizes.
HCC - 1q and 8p amp, 1p and 8p deletions
Neuroblastoma - del 1p and gain of 17q
Tumour DNA more fragmented = <180bp
UCSC table browser to identify target sequences, in-silico PCR to test predicted outcome.

22
Q

What is Hepatocellular carcinoma?

A

One of the leading causes of cancer-related deaths worldwide. Currently has poor survival due to late diagnosis. High recurrence rate 50% in 5 years.
Wide range of genetic changes, unknown pathology. 8q is second most commonly amplified. 1q gain and deletion are most common finding.

23
Q

Principles of patient centred counselling

A

Maintain a patients autonomy
Help patients reach the best rescissions for them as individuals
Try to be non-directive
May lean more towards shared decision making in practice as patients frequently want ‘expert’ input.

24
Q

Describe one test performed by Clinical biochemistry and why it is used (diabetes)

A

Diabetes is a metabolic disorder, high blood sugar over a prolonged period of time.
Type1 = autoimmune, rapid onset, attack own pancreatic cells, preventing production of insulin.
Type 2 = 90% of cases, not enough insulin produced or doesn’t react appropriately to insulin. Fatigue, weight loss, slow wound healing. Progressive, middle aged-elderly.

Testing = fasting plasma glucose. >7mmol/g or random glucose >11 on 2+ occasions with diabetes symptoms is enough to be diagnostic.
Glucose is phosphorylated to G6P-DH and then oxidised to 6-phosphogluconate which reduces NAD+ to NADH in a manner proportional to the amount of glucose present.
Oral glucose tolerance test - glucose solution taken after fasting, testing 2 hrs later into fluoride coated tube to prevent blood enzymes metabolising any glucose present.

25
Q

Define an inappropriate referral

A

A request for a test which is unsuitable for the referral reason, either due to the patients age, clinical phenotype or sample requirements.
Eg. Lymphoma testing of BM before tumour without evidence of marrow infiltration.
Testing of <16 y/o asymptomatic for FRAX
Testing not requested by appropriate clinician eg. Huntington must be requested by Neurologist or Clinical genetics - appropriate counselling.
Request for microarray when only LitHep received

26
Q

Types of audit and their benefits

A

Internal:
Vertical - follows a sample the whole way through a pathway. Allows auditors to look at all factors affecting a sample.
Horizontal - looks at one process for a larger number of samples. Allows identification of any inconsistencies in the application of a procedure.
Ad hoc - define own parameters. Allows responsive investigation of trends in any area.

External:
NEQAS - enables standardisation of testing across multiple diagnostic labs, identifies superior and inferior testing strategies/technologies. Ensures patients receive a more consistent service across country. Enables further learning.

27
Q

What must you consider to include on a report?

A

Referring clinician
Sample/patient info
Referral reason
Testing performed - check that no further testing outside of scope has been requested
Headline result - may include overall prognostic info
Written summary of testing undertaken with interpretation
Recommend any further testing required
Referral to any other departments
Limits of detection

28
Q

What is the testing strategy for CML?

A

3 day FISH for BCR/ABL1 and Karyotype within 7 days to check if standard rearrangement. Chromosomes to check for CML are 9’s, 22s, 3’s and 17s.

RT-PCR is performed to identify the type of transcripts which can me monitored to asses response to therapy

29
Q

What is the testing strategy for ALL

A

Is it B-ALL or T-ALL, <25 y/o or older.
T-ALL and adult B-ALL = FISH MLL and BCR/ABL1 (poor) - Array and further FISH may be required.
Some cells are prone to apoptosis so shorter culturing times required.

Always reported to WHO categories
Moorman et al integrated prognosis
Favourable - high hyperdiploidy and ETV6/RUNX1
High risk - BCR/ABL, MLL, near haploidy, low hypodiploidy, iamp21, tCF3-HLF
Intermediate - all others

30
Q

What is the testing strategy for AML

A

Karyotype and FISH (MLL and MECOM - if paediatric ETV6 also)

31
Q

Describe Maternal UPD 14 and how it is caused

A

UPD14 (Temple Syndrome) - imprinting disorder with mild phenotype of pre/postnatal growth retardation, Devdel, hypotonia, truncated obesit and early onset of puberty, adult short stature.

Can be caused by:

  1. Trisomic rescue
  2. Monosomy duplication via non-disjunction
  3. Gamete complementation - by chance a gamete missing one pair of chromosomes meets a gamete that contains two copies of that pair.
32
Q

Prader-Willi/Angelmen syndrome are caused by?

A

Failure of chromosomes to separate during gametogenisis (non-disjunction) = trisomy/monosomy. Can be caused by robertsonian translocation, or creation of isochromosome.

UPD15 maternal = Prader Willi (neonatal hypotonia, failure to thrive, devdel, obesity, behavioural issues)

UPD15 paternal = Angelman syndrome (sever ID, absent speech, ataxic movement, seizures, happy disposition)

33
Q

What is Cri-du-Chat and how is it diagnosed

A

Deletion of 5p-, infants will have a high pitched cry that sounds like a cat, moon face, broad nasal bridge, epicanthic folds, microcephaly.

Most deletions (80-90%) are paternal, may occur in sperm development, de novo.

Can be detected by microarray, FISH or Karyotype.

34
Q

Name a chromosome deletion syndrome (Wolf-Hirschhirn)

A

Wolf-Hirschhorn del 4p16.3 = low birth weight, hypotonia, motor delay, craniofacial abnormalities.

Usually de novo, early in embryonic development.

35
Q

What types of segregation can a balanced translocation undergo at meiosis

A
  1. Alternate segregation - only segregation that will result in normal phenotype (ROUGHLY EQUAL TRANS AND CENTRIC SEGMENT SIZES)
  2. Adjacent 1 - adjacent non-homologues = unbalanced gametes, both have duplications and deletions and are likely not viable - check schinzel. (MOST LIKELY IF TRANS SEGMENTS ARE SMALL)
  3. Adjacent 2 - adjacent homologues = unbalanced gametes, both have duplications and deletions and are likely not viable - check schinzel. ( MOST LIKELY IF CENTRIC SEGMENTS ARE SMALL)
  4. 3:1 segregation - (QUADRIVALENT IS LOPSIDED involving small acrocentric chromosome eg T13, 18, 21)
36
Q

What disorder do you test for JAK2 and CALR? How do we test?

A

MPNs: polycythemia vera, essential thrombocytosis, primary myelofibrosis.

May present with fatigue, sweats, increased spleen size.

Testing is allele specific PCR = primers bind specific location on gene where snp is expected, amplification occurs through cycles of denaturing, annealing and extension to amplify products. Two forward primers and one reverse. The two forward primers are targeted to either the WT or mutant.

JAK2 v617f
CALR 5bp ins 52bp del

37
Q

What is pyrosequencing?

A

Sequencing by synthesis: method that detects light emitted during the sequential addition of nucleotides during the synthesis of a complimentary strand, via the release of pyrophosphate in real time. Sulfurylase converts released pyrophosphate to ATP. This ATP drives luciferase mediated conversion of luciferin to oxyluciferin which generates light in proportional amounts. dNTPs are added sequentially to produce a run of peaks, proportional in height to the number of dNTPs added of each type.

38
Q

What is the use of KRAS/NRAS/BRAF testing in colorectal cancer?

A

Activating mutations in these genes provide treatment related information for patients undergoing anti-epidermal growth factor (EGFR), cetuximab or panitmumab treatment. Patients with mutations in RAS genes will not benefit from anti-EGFR therapies. WT and BRAF mutated tumours have targeted treatments available.

Mutations in these genes are mutually exclusive and occur globally in 55-60% of colorectal cancers.

39
Q

How do you design primers

A

Primers may be identified from peer reviewed publications, commercial providers or designed in house using open source tools such as Primer-BLAST or by manual examination of the sequence

40
Q

What are the principles of primer design, things to consider

A

Primer must begin at least 50 bp either side of a sequence for sequencing.
Minimum primer length of 18bp - enough to be sequence specific but not so long as to have a high Tm.
Primer pairs should not be complimentary to one another, particularly at their 3’ end as primer diners can form.
The presence of c/g bases in the last 5-6 bases helps promote specific binding due to stronger binding.
GC content and Tm of primer pairs should be closely matched
Check for SNPs - SNPcheck, Ensembl, Alamut or gnomAD

41
Q

What would you use the following databases for?

A

Decipher - similar patient cases and phenotypes, overlapping CNV syndromes/DDD variants, list of genes within call, some functional scoring of haploinsufficiency/missense tolerance and links out to other databases.
PanelApp - is the gene included in any relevant panels - curated
Locus specific databases - known variants within genes of interest
Clinvar - database of variants relating to disease
GnomAD- database on normal variation
Ensembl - genome browser, look up relevant transcripts
Igv - genome browser
Mutalyzer - check mutation nomenclature according to HGVS

42
Q

How would you take a patient family history? And why is it important?

A

Set out the agenda for the appointment
Build a rapport, help the patient get comfortable
Best if informed of the information required before the appointment
Move sequentially through the family tree, following one lineage to the end eg mums side, befor moving back to where the tree last divided.
Ask the patient to confirm what’s been recorded as you go along.
Names, date of birth, date and cause of death, relationships, any prior genetic testing, and clinical phenotypes or disease.
Explain why some information might not seem relevant how it applies to the patients genetic profile or risk etc.
Some topics may bring up strong emotions,

43
Q

Describe cell culture technique for constitution blood samples?

A

Synchronised culture -
Add to media ( RPMI, Fetal calf serum, PHA, antibiotic) PHA stimulates cell division.
Use alternate media batches when setting up multiple or doing reset cultures
Incubate at 37°c - 48hrs later add Thymidine ( arrests cells at G1/S boundary)
18 hours later add D.O.C (releases cell block so all cells at same stage of replication)
Harvest - add colcemid ( prevents spindle formation during mitosis and metaphase arrest)
Add KCL to swell and burst the cells.

44
Q

How does bone marrow culture differ to blood culture?

A

No synchronisation for Dir and 24hr - colcemid added added at different time lengths for different cultures.
Thy - like a sync for bloods.

45
Q

Describe the process of magnetic bead extraction

A
46
Q

How do you critically appraise literature

A

Use a critical appraisal framework, including a series of questions:

  • Is the study scientifically valid?
  • What are the results?
  • Are the results useful?

Taking a structured approach to appraisal, using frameworks and tools designed to assess within a particular research approach, enables us to carry out a measured (or fair) assessment of a paper’s strengths and limitations.

47
Q

What is confounding

A

A confounding variable is a variable that is independently associated with both the exposure/risk factor and outcome such that any relationship between the risk factor and outcome cannot be deemed causal if confounding variables have not been taken into account.
For instance, in a case-control study examining the relationship between cigarette smoking and pancreatic cancer, we may want to match the cases and controls with respect to the possible confounding variables of age and gender